Dublin, Aug. 13, 2024 (GLOBE NEWSWIRE) -- The "Rare Kidney Diseases Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Disease Indications, Type of Molecule, Type of Biologics, Route of Administration, Type of Therapy, Key Geographical Regions, Leading Drug Developers and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.
The global rare kidney diseases market is estimated to grow from $3.9 billion in 2024 to $12.1 billion by 2035, representing a CAGR of 11%, during the forecast period 2024-2035.
This research study consists of industry trends, detailed rare kidney diseases market analysis, key market insights, partnerships and collaborations analysis, funding and investments, clinical trial analysis and market impact analysis. The report includes rare diseases market forecast and opportunity analysis.
Rare kidney diseases are a group of conditions, with at least 150 different disorders falling into this category. In Europe, a rare kidney disease is defined as rare when the prevalence is less than 1 in 2000 people and in the US, the disease is designated rare when less than 200,000 people are affected. It is worth mentioning that in 2020, of more than 8,000 individuals diagnosed with rare kidney disease, only 500 received treatment for a rare kidney disease received treatment. Studies have also shown that 12% individuals with kidney failure suffer from a rare kidney disease leading to chronic debilitation and morbidity. Thereby, several initiatives have been taken by stakeholders to promote the development of therapeutics focused on rare kidney diseases.
It is worth mentioning that, since 2019, around USD 8 billion has been invested in companies developing therapies for rare kidney diseases. However, advancements in the diagnosis and treatment of rare kidney diseases have been hampered by several factors, including limited patient population, lack of prognostic biomarkers, clinical heterogeneity, and insufficient model organisms. To address such challenges, several promising advancements have been made in this domain.
For instance, the emergence of precision medicine (genomic sequencing and personalized therapies) has enabled the targeted treatment of rare kidney diseases, drug repurposing involving the identification of new therapeutic targets and leveraging the pharmacological properties for existing drugs which has emerged as a cost-effective strategy for treating rare kidney diseases. It is worth mentioning that the integration of artificial intelligence (AI) and machine learning algorithms to optimize the personalized treatment of rare kidney diseases is one of the prominent examples of technological advancements in the rare kidney diseases market.
Over the past few years, a number of rare kidney disease drugs targeting a myriad of indications have received approval from various regulatory authorities, globally. In 2023, the Food and Drug Administration (FDA) granted approval for Elfabrio (developed by Protalix BioTherapeutics) for the treatment of Fabry Disease. Additionally, the FDA granted approval to Tarpeyo (developed by Calliditas Therapeutics) for the treatment of IgA Nephropathy. Given the lucrative opportunity associated with these drugs, the rare kidney diseases market has gained attention of both private and public investors in the past few years leading to the substantial market growth during the forecast period.
Rare Kidney Diseases Market Key Segments
Market Share by Target Disease Indication
The global rare kidney diseases market is segmented into various target disease indication, such as Nephrotic Syndrome, Hepatorenal Syndrome, Distal Renal Tubular Acidosis, Fabry Disease, Lupus Nephritis, Atypical Hemolytic Uremic Syndrome, Immunoglobulin A Nephropathy, Autosomal Dominant Polycystic Kidney Disease, Autosomal Recessive Polycystic Kidney Disease, C3 Glomerulopathy, Membranous Nephropathy, Focal Segmental Glomerulosclerosis and others. The Fabry disease occupies the largest share in 2024 and is expected to remain dominant during the forecast period. This can be attributed to the high incidence rate of Fabry disease, affecting about 1 in 15,000 people. Further, Lupus Nephritis segment is estimated to grow at the highest CAGR (>8%) from 2024 to 2035.
Market Share by Type of Molecule
This segment highlights the distribution of the rare kidney diseases market across different types of molecules, such as biologics and small molecules. The small molecules segment occupies the largest share in 2024 and is expected to remain dominant during the forecast period. This can be primarily attributed to the fact that small molecules have low molecular weight and can easily pass through cell membranes to reach intracellular targets, thereby advancing new capabilities to create advanced potential therapies.
Market Share by Type of Biologics
This segment highlights the distribution of the rare kidney diseases market across different types of biologics, such as monoclonal antibodies and proteins. The monoclonal antibodies segment occupies the largest share in 2024 and is expected to remain dominant during the forecast period. This can be primarily attributed to the physiological properties of monoclonal antibodies, including selectivity, specificity, stability, and ability to block specific protein-protein interactions.
Market Share by Route of Administration
The global rare kidney diseases market is categorized into oral, intravenous, and subcutaneous route of administration. Owing to their safety and convenient nature, the segment for oral route of administration is likely to grow at a higher CAGR (11%) as compared to other routes of administration in the coming years.
Market Share by Type of Therapy
The rare kidney diseases market is categorized into monotherapy and combination therapy. Owing to their safety and convenient nature, the segment for combination therapy is likely to grow at a higher CAGR (75%) as compared to monotherapy in the coming years.
Market Share by Geography
This segment highlights the distribution of rare kidney diseases market across key geographical regions, including North America, Europe, Asia-Pacific, and rest of the world. It is worth highlighting that currently North America captures 50% of the current total rare kidney diseases market share. Further, market in Europe is expected to grow at a CAGR of close to 6% during the forecast period. This can be attributed to the fact that European countries, including Germany, France, and Spain have a growing incidence rate for such diseases. Further, several investments and initiatives have been taken by government authorities to promote the rare kidney diseases market.
Rare Kidney Diseases Market Key Insights
The report features an extensive study of the current market landscape, market size and future opportunities associated with developers within the rare kidney disease, during the given forecast period. The market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of rare kidney diseases industry. Key takeaways of the rare kidney diseases market report are briefly discussed below.
Competitive Landscape of Drug Developers for Rare Kidney Diseases
The current market landscape features the presence of over 115 companies involved in developing various rare kidney disease therapies. In addition, more than 20 rare kidney disease drugs have been commercialized for targeting various indications with more than 115 therapies in the clinical stage of development. Furthermore, the rare kidney disease market features the presence of small, mid-sized and large companies having the required expertise to develop and commercialize therapies.
Rare Kidney Diseases Market Trends: Increasing Partnerships and Collaborations to Foster Progress and Innovation
The rare kidney disease drug developers have forged several partnerships with other stakeholders in order to enhance their drug portfolios. The growing need for rare kidney disease therapies is evident from the rise in partnership activity in the rare kidney disease market. It is worth highlighting that a significant increase has been witnessed in 2023, wherein majority of the deals were focused on product and technology licensing, followed by the instances of stakeholders collaborating for research and development. In November 2023, Cabaletta Bio entered into a technology licensing agreement with Cellares to manufacture CABA-201, for treating Lupus Nephritis. This can be attributed to the incessant efforts of stakeholders to further advance the development of their drugs across different phases of preclinical and clinical development. Such partnerships are expected to drive significant rare kidney diseases market growth during the forecast period.
Key Drivers of the Rare Kidney Diseases Market
The funding raised, government initiatives and the likely future potential of rare kidney disease therapies will primarily drive the rare kidney diseases market. It is interesting to note that over the past few years, development efforts in rare kidney diseases domain have been adequately supported by various government and non-government agencies. Venture capital firms and other key investors have invested around USD 8 billion in the last 5 years in the companies working towards development of therapeutics targeting rare kidney diseases.
Also, the increasing awareness and understanding of rare kidney diseases have strengthened this domain with several events being conducted by stakeholders. For instance, in September 2023, the American Kidney Fund (AKF) conducted a general awareness campaign for C3 Glomerulopathy and IgA Nephropathy, which was sponsored by Novartis. Such initiatives will increase the awareness amongst the public, improve the diagnosis and treatment rates, driving the rare kidney disease market.
Rare Kidney Diseases Market Size: Drugs Targeting Fabry Disease Hold the Largest Market Share
The global market opportunity for rare kidney diseases is estimated to be more than $3.9 billion in 2024 which is anticipated to grow at CAGR of 11% during the forecast period 2024-2035. The market growth is primarily fueled by increasing incidence of Fabry diseases, encouraging the stakeholders to develop drugs with higher efficacy rates.
North America Holds the Largest Share of the Rare Kidney Diseases Market
In 2024, North America is anticipated to capture close to 50% market share of the overall rare kidney diseases market. In recent years, research activity for rare kidney diseases has witnessed a tremendous increase in North America. Further, it is worth highlighting that, market in Asia-Pacific is likely to grow at a CAGR of 8.5% during the forecast period 2024-2035.
Leading Players in the Rare Kidney Diseases Market
Leading Drug Developers
- Alexion Pharmaceuticals
- Amicus Therapeutics
- Aurinia Pharmaceuticals
- GSK
- Otsuka PharmaceuticalMallinckrodt Pharmaceuticals
- Novartis
- Otsuka Pharmaceutical
- Roche
- Sanofi
- Travere Therapeutics
- Other Players
Leading Market Players
- Alexion Pharmaceuticals
- Chinook Therapeutics
- Horizon Therapeutics
- Jiangsu Hengrui Pharmaceuticals
- Novartis
- Omeros
- Roche
- Sanofi
- Travere Therapeutics
- ZyVersa Therapeutics
- Advicenne
- Apellis Pharmaceuticals
- argenx
- Astellas Pharma
- Boehringer Ingelheim
- Calliditas Therapeutics
- GSK
- Mallinckrodt Pharmaceuticals
- Synlogic
- Takeda
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 240 |
| Forecast Period | 2024 - 2035 |
| Estimated Market Value (USD) in 2024 | $3.9 Billion |
| Forecasted Market Value (USD) by 2035 | $12.1 Billion |
| Compound Annual Growth Rate | 11.0% |
| Regions Covered | Global |
Key Topics Covered:
1. RESEARCH METHODOLOGY
2. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3. EXECUTIVE SUMMARY
4. INTRODUCTION
5. MARKET LANDSCAPE
5.1. Rare Kidney Disease Therapies: Market Landscape
5.1.1. Analysis by Phase of Development
5.1.2. Analysis by Route of Administration
5.1.3. Analysis by Type Molecule
5.1.4. Analysis by Target Disease Indication
5.1.5. Analysis by Type of Biologic
5.1.6. Analysis by Type of Therapy
5.1.7. Analysis by Dosing Frequency
5.1.8. Analysis by Target Patient Segment
5.1.9. Key Facts on Drug Designation
6. RARE KIDNEY DISEASE THERAPIES: DETAILED COMPANY PROFILES
6.1. Chapter Overview
6.1.1. Alexion Pharmaceuticals
6.1.2. Chinook Therapeutics
6.1.3. Horizon Therapeutics
6.1.4. Jiangsu Hengrui Pharmaceuticals
6.1.5. Novartis
6.1.6. Omeros
6.1.7. Roche
6.1.8. Sanofi
6.1.9. Travere Therapeutics
6.1.10. ZyVersa Therapeutics
7. RARE KIDNEY DISEASE THERAPIES: SHORT COMPANY PROFILES
7.1. Chapter Overview
7.1.1 Advicenne
7.1.2. Apellis Pharmaceuticals
7.1.3. argenx
7.1.4. Astellas Pharma
7.1.5. Boehringer Ingelheim
7.1.6. Calliditas Therapeutics
7.1.7. GSK
7.1.8. Mallinckrodt Pharmaceuticals
7.1.9. Synlogic
7.1.10. Takeda
8. COMPANY COMPETITIVENESS ANALYSIS
9. PARTNERSHIPS AND COLLABORATIONS
10. FUNDING AND INVESTMENTS
11. CLINICAL TRIAL ANALYSIS
12. CLINICAL COMMERCIAL ATTRACTIVENESS
13. KEY OPINION LEADERS
14. CASE STUDY
15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
16. RARE KIDNEY DISEASE MARKET
17. RARE KIDNEY DISEASE MARKET, BY TARGET DISEASE INDICATION
18. RARE KIDNEY DISEASE MARKET, BY TYPE OF MOLECULE
19. RARE KIDNEY DISEASE MARKET, BY TYPE OF BIOLOGICS
20. RARE KIDNEY DISEASE MARKET, BY ROUTE OF ADMINISTRATION
21. RARE KIDNEY DISEASE MARKET, BY TYPE OF THERAPY
22. RARE KIDNEY DISEASE MARKET, BY GEOGRAPHY
23. RARE KIDNEY DISEASES MARKET, SALES FORECAST OF DRUGS
23.1. Chapter Overview
23.2. Approved Rare Kidney Disease Therapies Market: Sales Forecast
23.2.1. Agalsidase Beta BS I.V. Infusion / Agalsidase beta / JR-051 Sales Forecast
23.2.2. Benlysta / Belimumab Sales Forecast
23.2.3. Elfabrio / PRX-102 / Pegunigalsidase Alfa Sales Forecast
23.2.4. FILSPARI / Sparsentan / RE-021 Sales Forecast
23.2.5. Galafold / Migalastat / AT1001 Sales Forecast
23.2.6. LUPKYNIS / Voclosporin Sales Forecast
23.2.7. Sibnayal / ADV7103 Sales Forecast
23.2.8. Tarpeyo / Nef-301 / Nefigard-OLE / Nefecon / Kinpeygo Sales Forecast
23.2.9. TERLIVAZ / Terlipressin Sales Forecast
23.2.10. Tolvaptan / Jynarque / Samsca / OPC-156 Sales Forecast
23.2.11. ULTOMIRIS / Ravulizumab-cwvz Sales Forecast
23.3. Phase III Rare Kidney Disease Therapies Market: Sales Forecast
23.3.1. APL-2 / Pegcetacoplan/ Aspaveli / EMPAVELI / SYFOVRE Sales Forecast
23.3.2. Atacicept / VT-001 Sales Forecast
23.3.3. Atrasentan / CHK-01 / Atrasentan Hydrochloride / ABT-627 / Xinlay Sales Forecast
23.3.4. FILSPARI / Sparsentan / RE-021 Sales Forecast
23.3.5. IONIS-FB-LRX / RO-7434656 / ASO Factor B / ISIS-696844 / RG6299 Sales Forecast
23.3.6. Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast
23.3.7. Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast
23.3.8. Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast
23.3.9. Lucerastat / ACT 434964 / OGT 923 Sales Forecast
23.3.10. MIL62 Sales Forecast
23.3.11. Obinutuzumab / Afutuzumab / GA101 / Gazyva / RO5072759 Sales Forecast
23.3.12. Obinutuzumab / Afutuzumab / GA101 / Gazyva / RO5072759 Sales Forecast
23.3.13. Repagermanium / DMX-200 Sales Forecast
23.3.14. Sibeprenlimab / VIS-649 Sales Forecast
23.3.15. SNP-ACTH / SNP ACTH (1-39) Sales Forecast
23.3.16. Telitacicept / RC18 Sales Forecast
23.3.17. Tolvaptan / Jynarque / Samsca / OPC-156 Sales Forecast
23.3.18. Venglustat / Ibiglustat / GZ402671 Sales Forecast
24. RARE KIDNEY DISEASES MARKET, BY LEADING DRUG DEVELOPERS
For more information about this report visit https://www.researchandmarkets.com/r/cj1g22
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
